Item 5. Other Information
Item 5. Other Information
Insider Trading Arrangements and Policies
During the quarter ended March 31, 2025, none
of the Company’s directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement”
or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, that was intended to satisfy
the affirmative defense conditions of Rule 10b5-1(c).
Item 6. Exhibits
The following exhibits are filed as part of, or
incorporated by reference into, this Quarterly Report.
Exhibit No.
Description
19.1***
Klotho
Neurosciences, Inc. Insider Trading Policy (incorporated by reference to Exhibit 19.1 filed by Klotho Neurosciences, Inc.’s
on Form 10-Q filed with the SEC on November 19, 2024).
31.1*
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section
302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification
of Principal Accounting and Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certification
of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
32.2**
Certification
of Principal Accounting and Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002
97.1***
Clawback
policy (incorporated by reference to Exhibit 97.1 filed by Redwoods on Form 10-K filed by the Registrant on April 17, 2024).
101.INS*
Inline XBRL Instance Document
101.SCH*
Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation
Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition
Linkbase Document
101.LAB*
Inline XBRL Taxonomy Extension Labels Linkbase
Document
101.PRE*
Inline XBRL Taxonomy Extension Presentation
Linkbase Document
104*
Cover Page Interactive Data File (Embedded
within the Inline XBRL document and included in Exhibit)
*
Filed herewith.
**
Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
***
Filed previously.
25
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KLOTHO NEUROSCIENCES, INC.
Date: May 14, 2025
By:
/s/ Joseph A. Sinkule
Name:
Joseph A. Sinkule
Title:
Chief Executive Officer
(Principal Executive Officer)
Date: May 14, 2025
By:
/s/ Jeffrey LeBlanc
Name:
Jeffrey LeBlanc
Title:
Chief Financial Officer
(Principal Accounting Officer)
26
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.